Rema P, Mathew Arun Peter, Suchetha S, Ahmed Iqbal
Division of Surgical Oncology, Regional Cancer Centre, Trivandrum, Kerala India.
Indian J Surg Oncol. 2017 Jun;8(2):146-149. doi: 10.1007/s13193-015-0472-2. Epub 2015 Oct 9.
Cervical cancer usually presents in advanced stages and is treated with chemoradiation. About 15-20 % patients present with local recurrence after chemoradiation. Radical surgical resection is the only treatment modality offering long term survival benefit in recurrent cervical cancer. The most common surgical option for these patients is pelvic exenteration. Radical hysterectomy may be done for patients with a small centrally located recurrence in the cervix with no infiltration of adjacent structures. The aim of this study was to evaluate the morbidity and survival outcome following radical hysterectomy and pelvic exenteration for recurrent cancer cervix. We retrospectively reviewed the medical records of our patients who underwent surgery for cancer cervix recurrence from January 2010 to December 2014. The postoperative morbidity was considered early if it happened in the initial 30 days of surgery and late if it occurred after 30 days. All patients were followed up till February 2015. Survival analysis was done using Kaplan- Meir method. Between January 2010 and December 2014, 20 patients with recurrent cervical cancer underwent radical surgical resection. The median age of the study group was 43 years (range 28-63 years). Seventeen patients had squamous cell carcinoma and 3 had adenocarcinoma. 13 underwent pelvic exenteration and 7 patients underwent radical type 2 hysterectomy with bilateral pelvic lymphnode dissection. In the exenteration group, 8 patients had anterior exenteration, 4 had total exenteration and one had posterior exenteration. Urinary diversion was done by ileal conduit in 8 patients, double barrel colostomy in two and wet colostomy in two patients. There were no immediate postoperative deaths. Operating time, blood transfusions needed and hospital stay was more in the exenteration group compared to radical hysterectomy patients. After pelvic exenteration post-operative complications were seen in 76.9 % of which the most common was of the urinary tract including 3 patients with pyelonephritis, 5 had renal insufficiency and 2 patients developed urinary fistulae. Post-operative morbidity was lower in radical hysterectomy patients. There were two patients in the hysterectomy group who developed vault recurrence while none in the exenteration group had local recurrence. The median follow up time was 19 months (range 9-53 months).Three year overall survival for the entire cohort was 43 %. Median survival time for the exenteration group was 28 months which was significantly higher than 14 months for the radical hysterectomy group. This study shows that radical surgical resection is feasible with good survival outcome and acceptable morbidity in recurrent cancer cervix patients. Radical hysterectomy can be done in selected patients but pelvic exenteration has better long-term survival but with the potential for both short- & long-term complications.
宫颈癌通常在晚期出现,采用放化疗进行治疗。约15%-20%的患者在放化疗后出现局部复发。根治性手术切除是复发性宫颈癌唯一能带来长期生存获益的治疗方式。对于这些患者,最常见的手术选择是盆腔脏器清除术。对于宫颈中央复发灶较小且未侵犯相邻结构的患者,可进行根治性子宫切除术。本研究的目的是评估复发性宫颈癌患者行根治性子宫切除术和盆腔脏器清除术后的发病率及生存结局。我们回顾性分析了2010年1月至2014年12月期间因宫颈癌复发而接受手术的患者的病历。如果术后并发症发生在手术的最初30天内,则视为早期并发症;如果发生在30天后,则视为晚期并发症。所有患者均随访至2015年2月。采用Kaplan-Meir法进行生存分析。2010年1月至2014年12月期间,20例复发性宫颈癌患者接受了根治性手术切除。研究组的中位年龄为43岁(范围28-63岁)。17例为鳞状细胞癌,3例为腺癌。13例行盆腔脏器清除术,7例患者行根治性Ⅱ型子宫切除术并双侧盆腔淋巴结清扫术。在盆腔脏器清除术组中,8例行前盆腔脏器清除术,4例行全盆腔脏器清除术,1例行后盆腔脏器清除术。8例患者采用回肠代膀胱术进行尿流改道,2例采用双腔结肠造口术,2例采用湿结肠造口术。术后无即刻死亡病例。与根治性子宫切除术患者相比,盆腔脏器清除术组的手术时间、输血量和住院时间更长。盆腔脏器清除术后,76.9%的患者出现术后并发症,其中最常见的是泌尿系统并发症,包括3例肾盂肾炎患者、5例肾功能不全患者和2例尿瘘患者。根治性子宫切除术患者的术后发病率较低。子宫切除术组有2例患者出现阴道残端复发,而盆腔脏器清除术组无局部复发病例。中位随访时间为19个月(范围9-53个月)。整个队列的三年总生存率为43%。盆腔脏器清除术组的中位生存时间为28个月,显著高于根治性子宫切除术组的14个月。本研究表明,根治性手术切除对于复发性宫颈癌患者是可行的且具有良好的生存结局和可接受的发病率。在部分患者中可进行根治性子宫切除术,但盆腔脏器清除术具有更好的长期生存效果,但存在短期和长期并发症的风险。